News

Clients

Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine

Key contribution to the acceleration of the development of ZENEO® Epinephrine Financial support includes mainly grants, as well as subsidized...

Clients

Kinarus Therapeutics signed CHF 1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management

May 11, 2023 7:00 AM Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics...

Clients

Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics

Netanya, Israel, March 30, 2023 – Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision...

Clients

AC Immune To Host Key Opinion Leader Webinar On Early Diagnosis And Prevention Of Alzheimer’s Disease

Webinar to take place on Tuesday, April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST  Lausanne, Switzerland, April 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical...

Clients

First MSCI index based Crypto ETP launched by ETC Group starts trading on XETRA

ETC Group MSCI Digital Assets Select 20 ETP (DA20) tracks performance of the top 20 digital assets, comprising around 85%...

Clients

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Lausanne, Switzerland, April 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases,...

Clients

Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development

Zurich, Switzerland, May 3, 2023 – Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life...

Clients

AC Immune Receives FDA Fast Track Designation For Anti-Amyloid-Beta Active Immunotherapy, ACI-24.060, To Treat Alzheimer’s Disease

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE...

Clients

Mithra Appoints Experienced Life Sciences Executive Christian Homsy* as Chairman

May 29, 2023 01:30 ET| Source: Mithra Pharmaceuticals Inge Beernaert appointed President of the Compensation and Nomination Committee Jacques Galloy appointed...

Clients

AC Immune Holds Annual General Meeting of Shareholders

June 23, 2023 AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board...

Clients

Crossject announces highly successful closing of its €8 million rights offering

Gross fundraising of approximately €8 million or 100% of the planned rights offering as proposed and announced on 30 April...

Clients

AC Immune And Takeda Sign Exclusive Option And License Agreement For Active Immunotherapy Targeting Amyloid Beta For Alzheimer’s Disease

May 13, 2024  PDF Version − Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active...

Clients

Crossject announces publication of clinical data on ZEPIZURE® in Neurology and Therapy

Clinical study performed in 2022 now published in peer-reviewed Neurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum®...

Clients

Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke

• First-in-class drug candidate evaluated in first eight patients Gosselies (Belgium), June 27, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company...